Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer

Inclusion Criteria: * Histologically confirmed non-small cell lung cancer with a clinical stage of IIIA * Candidate for chemoradiation and surgical resection * Measurable disease * Life expectancy \> 6 months * Normal organ and marrow function Exclusion Criteria: * Pregnant or breast-feeding * Prior therapy for lung cancer with chemotherapy * Prior chest radiation * Compromised pulmonary function * Severe neurovascular disease * History of high cardiac risk including unstable angina * History of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin or etoposide * Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive hear failure, unstable angina pectoris, clinically significant or serious cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * History of a different malignancy unless disease-free for at least 3 years and at low risk for recurrence. Individuals with the following cancers are eligible if diagnosed and treated within the past 3 years: cervical cancer in situ, non muscle-invasive bladder cancer, basal cell or squamous cell carcinoma of the skin * Subjects with HIV